| Ticker Details |
Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company developing and commercializing pharmaceutical products. The company's products include Bloxiverz, Vazculep, Akovaz, Karbinal ER, AcipHex Sprinkle, Cefaclor and Flexichamber.
|
| IPO Date: |
July 1, 1996 |
| Sector: |
Healthcare |
| Industry: |
Pharma |
| Market Cap: |
$1.81B |
| Activated in VL: |
False |
| Average Daily Range |
| Avg Daily Range: |
$0.23 | 3.02%
|
| Avg Daily Range (30 D): |
$0.27 | 1.78%
|
| Avg Daily Range (90 D): |
$0.25 | 1.89%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.69M |
| Avg Daily Volume (30 D): |
3.05M |
| Avg Daily Volume (90 D): |
1.76M |
| Trade Size |
| Avg Trade Size (Sh.): |
132 |
| Avg Trade Size (Sh.) (30 D): |
168 |
| Avg Trade Size (Sh.) (90 D): |
112 |
| Institutional Trades |
| Total Institutional Trades: |
1,336 |
| Avg Institutional Trade: |
$1.76M |
| Avg Institutional Trade (30 D): |
$2.43M |
| Avg Institutional Trade (90 D): |
$2.41M |
| Avg Institutional Trade Volume: |
.15M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.09M |
| Avg Closing Trade (30 D): |
$3.63M |
| Avg Closing Trade (90 D): |
$3.08M |
| Avg Closing Volume: |
171.57K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$
|
$.1
|
|
Diluted EPS
|
|
$
|
$.1
|
|
Revenue
|
|
$77.47M
|
$68.13M
|
|
Gross Profit
|
|
$81.58M
|
$61.76M
|
|
Net Income / Loss
|
|
$.02M
|
$9.67M
|
|
Operating Income / Loss
|
|
$1.94M
|
$8.88M
|
|
Cost of Revenue
|
|
$-4.12M
|
$6.37M
|
|
Net Cash Flow
|
|
$16.41M
|
$7.03M
|
|
PE Ratio
|
|
|
|
|
|
|
